1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Lactate Dehydrogenase

Lactate Dehydrogenase

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Lactate Dehydrogenase Related Products (21):

Cat. No. Product Name Effect Purity
  • HY-100681
    GSK2837808A
    Inhibitor ≥99.0%
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
  • HY-16214
    FX-11
    Inhibitor 98.44%
    FX-11 is a potent lactate dehydrogenase A (LDHA) inhibitor. FX-11 reduces ATP levels and induced oxidative stress and cell death. FX-11 can be used for cancer research.
  • HY-100742A
    (R)-GNE-140
    Inhibitor 99.20%
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
  • HY-100742
    GNE-140 racemate
    Inhibitor 99.66%
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor.
  • HY-111108
    LDH-IN-1
    Inhibitor 99.86%
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
  • HY-W040118
    Galloflavin
    Inhibitor 98.12%
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 µM (LDH-A) and 15.06 µM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production.
  • HY-124309
    NHI-2
    Inhibitor ≥99.0%
    NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
  • HY-145261
    hDHODH-IN-8
    Inhibitor
    hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.
  • HY-N2177
    3-Dehydrotrametenolic acid
    Inhibitor 99.86%
    3-​Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-​Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-​Dehydrotrametenolic acid induces apoptosis and has anticancer activity.
  • HY-139319
    LDHA-IN-3
    Inhibitor 99.81%
    LDHA-IN-3, as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer.
  • HY-W040073
    Nifurtimox
    Inhibitor 99.65%
    Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
  • HY-N7393
    Isomalt
    ≥98.0%
    Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes.
  • HY-100742B
    (S)-GNE-140
    Inhibitor 99.04%
    (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
  • HY-135658
    hDHODH-IN-1
    Inhibitor 99.61%
    hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor. hDHODH-IN-1 has anti-inflammatory effect.
  • HY-N2498
    Glomeratose A
    Inhibitor 99.79%
    Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia.
  • HY-115875
    LDHA-IN-5
    Inhibitor
    LDHA-IN-5 is a novel, potent, dual GO/LDHA inhibitor for primary hyperoxaluria.
  • HY-18968
    LDHA-IN-4
    Inhibitor
    AZ-33 is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM.
  • HY-135654
    hDHODH-IN-2
    Inhibitor
    hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor. hDHODH-IN-1 has anti-inflammatory activity.
  • HY-W040073S
    Nifurtimox-d4
    Inhibitor
    Nifurtimox-d4 is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
  • HY-135648
    PfDHODH-IN-1
    Inhibitor 99.85%
    PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.